Hospira's Retacrit effective in chemotherapy-induced anemia
USA-based Hospira (NYSE: HSP), a leading provider of generic injectable drugs and infusion technologies, announced that its biosimilar epoetin, Retacrit (epoetin zeta), was effective in the management of chemotherapy-induced anemia in patients with solid tumors, lymphoma and myeloma.
Retacrit was approved in Europe in 2007 as a biosimilar medicine to the reference biological product, epoetin alfa, US biotech giant Amgen’s (Nasdaq: AMGN) brand Epogen.
The study, conducted in France to treat oncology patients was prospective and observational, among 2,310 adult patients of whom 99.9% received epoetin zeta. It demonstrated that more than 80% of patients receiving Retacrit achieved a pre-defined Hb response in a real-world clinical setting, which was maintained at six months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze